Silvia Buonamici
C4 Therapeutics (United States)(US)
Publications by Year
Research Areas
RNA Research and Splicing, RNA modifications and cancer, Acute Myeloid Leukemia Research, RNA and protein synthesis mechanisms, Fibroblast Growth Factor Research
Most-Cited Works
- → The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1(2017)581 cited
- → SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition(2015)562 cited
- → Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma(2010)553 cited
- → H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers(2018)500 cited
- → The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia(2007)485 cited
- → Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point(2015)458 cited
- → Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1(2018)436 cited
- → Molecular pathogenesis of T-cell leukaemia and lymphoma(2008)427 cited
- → Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation(2016)384 cited
- → A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia(2011)379 cited